DDInter1951 DDInter626
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients. Treatment options for chronic hepatitis C have advanced significantly since 2011, with the development of direct-acting antivirals (DAAs) such as elbasvir. Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.[synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs. Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir. Despite this disadvantage elbasvir is still effective against HCV, particularly when paired with [grazoprevir]. Elbasvir is available as a fixed-dose combination product with [grazoprevir] (tradename: Zepatier) used for the treatment of chronic hepatitis C. Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions in the NS5A protein and previous treatment failure with [ribavirin], [peginterferon alfa-2a], [peginterferon alfa-2b], or other NS3/4A inhibitors like [boceprevir], [simeprevir], or [telaprevir]. Elbasvir and [grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment.. SVR and eradication of HCV infection are associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of hepatocellular carcinoma, and reduced all-cause mortality. In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication of SARS-CoV-2, the human coronavirus responsible for the COVID-19 pandemic. While these results are suggestive of antiviral efficacy, follow-up clinical trials are required to validate elbasvir as a potential therapy against SARS-CoV-2.
Warfarin {u} (Compound) resembles {v} (Compound) Benzyl Benzoate
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Warfarin {u} (Compound) resembles {v} (Compound) Fenoprofen
Warfarin {u} (Compound) binds {v} (Gene) CYP2C8
Warfarin {u} (Compound) upregulates {v} (Gene) CDK6
Warfarin {u} (Compound) is included by {v} (Pharmacologic Class) Vitamin K Inhibitors
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Meloxicam
Warfarin (Compound) resembles Benzyl Benzoate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Warfarin (Compound) resembles Fenoprofen (Compound)
Warfarin (Compound) binds CYP2C8 (Gene)
Warfarin (Compound) upregulates CDK6 (Gene)
Warfarin (Compound) is included by Vitamin K Inhibitors (Pharmacologic Class)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine
Warfarin may lead to a major life threatening interaction when taken with Meloxicam